{
    "organizations": [],
    "uuid": "cd288309609421378561207d1473d936bcef013f",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/03/globe-newswire-gw-pharmaceuticals-to-report-second-quarter-financial-results-and-host-conference-call-on-8-may-2018.html",
    "ord_in_thread": 0,
    "title": "GW Pharmaceuticals to Report Second Quarter Financial Results and Host Conference Call on 8 May,",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "LONDON, May 03, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 8 May, 2018 its second quarter financial results for the period ending 31 March, 2018. GW will also host a conference call the same day at 4:30 p.m. EDT. Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website ( www.gwpharm.com ) shortly after the call.\nAbout GW Pharmaceuticals plc and Greenwich Biosciences\nFounded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex (cannabidiol), for which GW has submitted regulatory applications in the U.S. and Europe for the adjunctive treatment of Lennox-Gastaut syndrome and Dravet syndrome. The Company continues to evaluate Epidiolex in additional rare epilepsy conditions and currently has ongoing clinical trials in Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a US Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia. For further information, please visit www.gwpharm.com .\nEnquiries:\nGW Pharmaceuticals plc Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570\nSource: GW Pharmaceuticals plc",
    "published": "2018-05-03T15:37:00.000+03:00",
    "crawled": "2018-05-03T15:41:09.025+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "london",
        "may",
        "globe",
        "newswire",
        "gw",
        "pharmaceutical",
        "plc",
        "nasdaq",
        "gwph",
        "gw",
        "company",
        "biopharmaceutical",
        "company",
        "focused",
        "discovering",
        "developing",
        "commercializing",
        "novel",
        "therapeutic",
        "proprietary",
        "cannabinoid",
        "product",
        "platform",
        "announce",
        "may",
        "second",
        "quarter",
        "financial",
        "result",
        "period",
        "ending",
        "march",
        "gw",
        "also",
        "host",
        "conference",
        "call",
        "day",
        "edt",
        "conference",
        "call",
        "information",
        "provided",
        "financial",
        "result",
        "press",
        "release",
        "replay",
        "call",
        "also",
        "available",
        "company",
        "website",
        "shortly",
        "call",
        "gw",
        "pharmaceutical",
        "plc",
        "greenwich",
        "bioscience",
        "founded",
        "gw",
        "biopharmaceutical",
        "company",
        "focused",
        "discovering",
        "developing",
        "commercializing",
        "novel",
        "therapeutic",
        "proprietary",
        "cannabinoid",
        "product",
        "platform",
        "broad",
        "range",
        "disease",
        "area",
        "gw",
        "along",
        "subsidiary",
        "greenwich",
        "bioscience",
        "advancing",
        "orphan",
        "drug",
        "program",
        "field",
        "epilepsy",
        "focus",
        "epidiolex",
        "cannabidiol",
        "gw",
        "submitted",
        "regulatory",
        "application",
        "europe",
        "adjunctive",
        "treatment",
        "syndrome",
        "dravet",
        "syndrome",
        "company",
        "continues",
        "evaluate",
        "epidiolex",
        "additional",
        "rare",
        "epilepsy",
        "condition",
        "currently",
        "ongoing",
        "clinical",
        "trial",
        "tuberous",
        "sclerosis",
        "complex",
        "infantile",
        "spasm",
        "gw",
        "commercialized",
        "world",
        "first",
        "cannabinoid",
        "prescription",
        "drug",
        "nabiximols",
        "approved",
        "treatment",
        "spasticity",
        "due",
        "multiple",
        "sclerosis",
        "numerous",
        "country",
        "outside",
        "united",
        "state",
        "company",
        "planning",
        "u",
        "phase",
        "trial",
        "company",
        "deep",
        "pipeline",
        "additional",
        "cannabinoid",
        "product",
        "candidate",
        "includes",
        "compound",
        "phase",
        "trial",
        "epilepsy",
        "glioblastoma",
        "schizophrenia",
        "information",
        "please",
        "visit",
        "enquiry",
        "gw",
        "pharmaceutical",
        "plc",
        "stephen",
        "schultz",
        "vp",
        "investor",
        "relation",
        "source",
        "gw",
        "pharmaceutical",
        "plc"
    ]
}